- CytoReason, an Israeli AI disease model company, raises $80 million in funding.
- Nvidia Corp. participates in the funding round to expand CytoReason’s AI model applications.
- Funding will support growth in molecular and clinical data capabilities.
- CytoReason aims to establish a U.S. office in 2024.
- Platform enhances drug development decision-making with speed, safety, and accuracy.
- Scientific breakthroughs featured in top journals like Nature and Cell.
- Six of the top 10 pharma companies use CytoReason’s technology.
- Partnership with Pfizer highlights strategic collaborations in R&D and drug development pathways.
Main AI News:
CytoReason Ltd., an Israeli artificial intelligence disease model company, announced today that it has successfully raised $80 million in its latest funding round, with Nvidia Corp. among the key investors. The funding aims to expand CytoReason’s applications of AI models, bolster its molecular and clinical data capabilities, and establish a new office in the United States later this year. Founded in 2016, CytoReason specializes in developing AI-driven disease models that provide critical insights into human diseases and their treatments.
The company’s platform is designed to facilitate the comparison of different treatments, prioritize drug development programs, and provide real-time updates that enable scientists and executives to make informed decisions about drug portfolios and performance. Central to CytoReason’s offering is its commitment to reducing research and development timelines while improving the probability of technical and regulatory success for life sciences companies engaged in pharmaceuticals, biotechnology, and medical devices.
By leveraging molecular-level insights and AI tools, CytoReason empowers therapeutic area leaders to adopt data-driven strategies in research and development, clinical practices, and treatment approaches. The platform’s emphasis on speed, safety, and accuracy supports crucial decision-making processes throughout the drug development lifecycle.
Scientific advancements facilitated by CytoReason’s technology have been prominently featured in renowned journals such as Nature, Cell, and Gut. In 2023 alone, CytoReason’s scientists authored 20 peer-reviewed articles across 16 journals, highlighting the company’s robust scientific output and technological prowess.
CytoReason’s impact extends globally, with six of the top 10 pharmaceutical companies utilizing its technology to drive insights and decisions in areas such as immunology, inflammation, immuno-oncology, and metabolism. Notable participants in CytoReason’s latest funding round include Pfizer Inc., Nvidia, OurCrowd Ltd., and Thermo Fisher Scientific Inc., underscoring the industry’s confidence in the company’s innovative approach.
Pfizer Inc., a longstanding partner of CytoReason since its initial investment of $20 million in 2022, emphasizes the transformative potential of technologies like artificial intelligence in advancing human health. Mikael Dolsten, Pfizer’s Chief Scientific Officer and President of Worldwide Research, Development, and Medical, noted the collaboration’s role in augmenting Pfizer’s own R&D capabilities and exploring new pathways for drug development.
Nvidia’s involvement reflects its strategic interest in CytoReason’s utilization of AI chips, which have demonstrated significant acceleration in computational workloads, particularly in predictive clinical insights and healthcare analytics. Kimberly Powell, Vice President and General Manager of Healthcare at Nvidia, highlighted the synergy between Nvidia’s accelerated computing platforms and CytoReason’s predictive capabilities, aiming to benefit more life sciences companies globally.
With this latest funding round, CytoReason has raised approximately $180 million to date, according to data from Tracxn, positioning the company for continued growth and innovation in AI-driven healthcare solutions.
Conclusion:
This substantial funding round, led by Nvidia, signifies growing confidence and investment in CytoReason’s advanced AI-driven disease models. The expansion into new markets and enhanced capabilities in molecular and clinical data analytics position CytoReason as a key player in accelerating research and development efficiencies across the life sciences sector. The strategic partnerships underscore the pivotal role of AI in driving transformative advancements in healthcare, shaping future innovations and industry standards.
